Article
The safety and efficacy of ledipasvir/sofosbuvir for the treatment of a nosocomial outbreak of HCV in patients with significant cardiovascular disease.
Antiviral therapy - 1 Jan 2016
Simon Tracey G, Kim Arthur Y, Stamm Luisa M, Liu Lin, Mo Hongmei, Doehle Brian, Pang Phillip S, Brainard Diana M, McHutchison John G, Gustafson Jenna, Lauer Georg M, Chung Raymond T
Abstract excerpt
BACKGROUND: There is an unmet need for interferon- and ribavirin-free treatment for chronic HCV infection in patients with comorbidities including cardiovascular disease (CVD). The aim of this study was to evaluate the rates of sustained virological response (SVR) and adverse events in a cohort of patients with nosocomially acquired HCV genotype-1b following 12 weeks of therapy with fixed-dose combination (FDC)...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.